Physician profile
Ruth A Freeman
NPI 1073502829
$1,237.70
in general payments reported to CMS, 2019-2025
21 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.65 · 2020: $207 · 2021: $122 · 2022: $348 · 2023: $231 · 2024: $88.43 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $315.87 | 2019-2025 | Mounjaro, Zepbound |
| Jazz Pharmaceuticals INC. | $175.36 | 2021-2022 | |
| Novo Nordisk INC | $135.96 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $103.84 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $99.22 | 2023-2025 | |
| Genzyme Corporation | $85.28 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $45.49 | 2019-2020 | |
| Abbott Laboratories | $39.27 | 2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $26.67 | 2022 | |
| Amgen INC. | $23.85 | 2022 | |
| Idorsia Pharmaceuticals US INC | $22.20 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $20.80 | 2025 | |
| Dexcom, INC. | $20.34 | 2022 | |
| Hologic Sales and Service, LLC | $19.35 | 2025 | Thinprep 2000 Processor |
| Genentech USA, INC. | $18.96 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $16.82 | 2019 | |
| Halozyme INC | $14.50 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $14.49 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.37 | 2022 | |
| Roche Diabetes Care, INC. | $13.16 | 2021 | |
| Linus Health, INC. | $11.90 | 2024 | Core Cognitive Evaluation |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.